Skip to main content

Specialty Pharmacy

  • Symphony Health Solutions study predicts 5% rise in statin prescriptions following new cholesterol guidelines

    SAN MATEO, Calif. – The number of patients receiving prescriptions for statins is expected to increase modestly following new cholesterol recommendations from the American College of Cardiology and the American Heart Association, according to a new report.

  • Merck drug approved for preventing fungal infections in immunosuppressed patients

    WHITEHOUSE STATION, N.J. — The Food and Drug Administration has approved a new tablet form of an antifungal drug made by Merck, the company said Tuesday.

    Merck announced the FDA approval of Noxafil (posaconazole) 100-mg delayed release tablets. The company also markets a 40-mg-per-milliliter oral suspension form of the drug. The new tablet formulation is designed to be taken in two 300-mg doses on the first day, followed by a 300-mg dose once per day.

  • AbbVie campaign focuses on women with HIV

    NORTH CHICAGO, Ill. – Drug maker AbbVie is launching an international awareness campaign focused on women living with HIV, the drug maker said Tuesday.

  • First wave of Certified Specialty Pharmacist credential recipients includes four from Diplomat

    FLINT, Mich. — Four pharmacists from Diplomat are among the 49 across the country who have received certification from the Specialty Pharmacy Certification Board, Diplomat said Monday.

    Diplomat said VP clinical services Gary Rice, clinical technology manager Michael Crowe, pharmacy manager Nicole Hubach and clinical manager Ryan Nolan had received the SPCB's Certified Specialty Pharmacist endorsement. The SPCB announced on Nov. 11 the first 49 pharmacists to become CSPs. The tests for the credential were administered in October.

  • FDA approves J&J's Olysio for hepatitis C

    TITUSVILLE, N.J. — The Food and Drug Administration has approved a new treatment made by Johnson & Johnson for hepatitis C, the drug maker said.

  • FDA gives regular approval to Pfizer's Xalkori

    NEW YORK — The Food and Drug Administration has granted regular approval to a new drug made by Pfizer for treating a form of lung cancer, the drug maker said.

  • Diplomat added to limited-distribution network for Cornerstone Therapeutics' Bethkis

    FLINT, Mich. — Cornerstone Therapeutics has added specialty pharmacy Diplomat to its limited-distribution network for a newly approved treatment for cystic fibrosis, Diplomat said Friday.

    Diplomat will distribute Bethkis (tobramycin inhalation solution), which received Food and Drug Administration approval in October for treating chronic bacterial lung infections caused by P. aeruginosa in cystic fibrosis patients.

  • Teva launches generic drug for cystic fibrosis patients

    JERUSALEM — Teva Pharmaceutical Industries has launched its generic version of a drug for patients with cystic fibrosis, the Israeli drug maker said Thursday.

    Teva announced the launch of tobramycin inhalation solution, a generic version of Novartis' drug Tobi. The Food and Drug Administration approved Teva's product last month. The drug is used to treat CF in patients whose lungs contain bacteria called Pseudomonas aeroginosa.

    Tobi had sales of about $350 million during the 12-month period that ended in June, according to IMS Health.

     

X
This ad will auto-close in 10 seconds